Alzamend Neuro Inc Market Cap ($6.03 Million)
Market Cap & Net Worth: Alzamend Neuro Inc (ALZN)
Alzamend Neuro Inc market cap. Alzamend Neuro Inc (NASDAQ:ALZN) has a market capitalization of $6.03 Million ($6.03 Million) as of November 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28139 globally and #5801 in its home market, demonstrating a 10.62% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alzamend Neuro Inc's stock price $1.25 by its total outstanding shares 4825723 (4.83 Million). Also see cash efficiency ratio of Alzamend Neuro Inc for how efficiently the company converts equity into cash flow.
Alzamend Neuro Inc Market Cap History (2021–2026)
Alzamend Neuro Inc market cap history from 2021 to 2026. Data shows change from $1.38 Billion to $6.03 Million (-74.64% CAGR). Check Alzamend Neuro Inc stock price for real-time trading data and today's change.
Index Memberships
Alzamend Neuro Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.00% | #802 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #2583 of 3165 |
Weight: Alzamend Neuro Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Alzamend Neuro Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Alzamend Neuro Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ALZN net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ALZN by Market Capitalization
Companies near Alzamend Neuro Inc in the global market cap rankings as of November 3, 2026. Also see total assets of Alzamend Neuro Inc for a full breakdown of the balance sheet.
Key companies related to Alzamend Neuro Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Alzamend Neuro Inc (2021–2026)
Market capitalization of Alzamend Neuro Inc from 2021 to today. Between 2021 and today, Alzamend Neuro Inc's market cap moved from $1.38 Billion to $ 6.03 Million, with a yearly change of -74.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $6.03 Million | -31.32% |
| 2025 | $8.78 Million | +56.90% |
| 2024 | $5.60 Million | -86.97% |
| 2023 | $42.95 Million | -89.50% |
| 2022 | $408.98 Million | -70.26% |
| 2021 | $1.38 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Alzamend Neuro Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.03 Million USD |
| MoneyControl | $6.03 Million USD |
| MarketWatch | $6.03 Million USD |
| marketcap.company | $6.03 Million USD |
| Reuters | $6.03 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Alzamend Neuro Inc
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, … Read more